Eversense® Continuous Glucose Monitor (CGM): A Post-Approval Study to Evaluate the Safety and Effectiveness of the Eversense® CGM System Used Non-Adjunctively (without another meter to compare)
Eversense® Continuous Glucose Monitor (CGM): A Post-Approval Study
Protocol Number: CTP-0039
Sponsor: Senseonics™
We are transitioning from the 180 day/6 month CGM to the 365/12-month CGM and are awaiting more details from Senseonics as they prepare a new protocol.
The system will consist of:
- Glucose Sensor, (approximately 3.5 mm x 18.3 mm length (Inserted under the skin in the triceps area of either arm)
- Battery-powered external Transmitter (Worn externally over sensor-placed with an adhesive patch) The transmitter vibrates to signal highs or lows.
- Mobile Medical Application (MMA) available on Android or iOS smartphone or smartwatch which will display glucose information.
Summary of Study Details:
The new protocol details have not been released yet, but details will be updated soon!
General Eligibility Criteria
Must have a smart phone that can download the Eversense App and be able to use the App
Other criteria have yet to be determined.
Compensation: TBD
If interested in learning more, please contact our Research Coordinator, Jamie Sigg, RD, CDCES, CRC at (303) 321-2644 x 214